Grabar Law Office is investigating claims on behalf of shareholders of Brainstorm Cell Therapeutics Inc.  (OTC: BCLI). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company focuses on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

As alleged in a federal securities fraud class action complaint, Brainstorm Cell Therapeutics Inc.  (OTC: BCLI), through certain of its officers, made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the Food and Drug Administration’s refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On September 15, 2025, certain key allegations in the amended class action complaint survived Defendants’ motion to dismiss. The claims include the investors' assertion that the company mischaracterized the FDA's views on the design of its relevant clinical trials and a claim that BrainStorm inaccurately described certain clinical subgroup analyses as "pre-specified" when they were not. The court also left in place a claim that the company distorted FDA feedback it received about what BrainStorm had described as a "floor effect" in its clinical trials. And the company cannot shed the claim it downplayed safety concerns, Judge Ho said Monday, noting that the complaint cites the FDA's safety concerns about the relevant studies.

Per Judge Ho, "In sum, the court concludes that Plaintiffs have sufficiently alleged false or misleading statements with respect to the FDA's views on trial design; pre-specification; the FDA's views on floor effects; and safety."

WHAT YOU CAN DO NOW: If you purchased Brainstorm Cell Therapeutics Inc.  (OTC: BCLI) prior to February 18, 2020, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.